The good, the bad, and the ugly: hyperprogression in cancer patients following immune checkpoint therapy

Editorial summary Immune checkpoint blockade therapy can elicit robust and durable responses in a variety of cancer types. While many patients do not respond, recent reports highlight a distinct group of patients whose tumors undergo rapid growth, leading to progressive disease and poor outcome. In...

Full description

Saved in:

Bibliographic Details
Published in:	Genome medicine Vol. 11; no. 1; pp. 43 - 3
Main Authors:	Sabio, Erich, Chan, Timothy A.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 24.07.2019 BioMed Central Ltd BMC
Subjects:	Antigen Antigens Antineoplastic Agents, Immunological - pharmacology Antineoplastic Agents, Immunological - therapeutic use Bioinformatics Biomarkers, Tumor - antagonists & inhibitors Biomedical and Life Sciences Biomedicine Cancer Cancer patients Cancer Research Comment Disease Progression Gene mutation Genetic aspects Human Genetics Humans Hyperprogression Immune checkpoint Immunomodulation - drug effects Immunomodulation - genetics Medicine/Public Health Metabolomics Molecular Targeted Therapy Mutation Neoplasms - drug therapy Neoplasms - etiology Neoplasms - pathology Risk Factors Systems Biology T cells T-Lymphocyte Subsets - drug effects T-Lymphocyte Subsets - immunology T-Lymphocyte Subsets - metabolism Treatment Outcome Tumor immune microenvironment and immunotherapy Tumors Antigen Immune checkpoint Mutation Hyperprogression T cells Cancer
ISSN:	1756-994X, 1756-994X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!